Close Menu

NEW YORK (GenomeWeb) – NantHealth's revenues fell 6 percent year over year during the second quarter, the company reported after the close of the market on Thursday.

For the three months ended June 30, total revenues declined to $22 million compared to $23.5 million in the same period a year earlier, which included $4 million from a since-ended large implementation in its connected devices business segment, according to NantHealth.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.